Navigation Links
Cancer-Causing Virus Synthesizes Protein To Help Sustain Itself In Host Cells

A protein that is synthesized by a cancer-causing virus enables it to bypass immune systems and infect the immune cells. This mechanism uses an unusual gene and also ensures that the virus persists in the host. //

The study examines the function of a protein called HBZ, which is made by the human T cell leukemia virus type 1 (HTLV-1), a retrovirus and a distant cousin to HIV, the cause of AIDS.

The findings indicate that HBZ enhanced the ability of HTLV-1 to establish a persistent infection in an animal host. The study by researchers with the Ohio State University Comprehensive Center and the College of Veterinary Medicine is published in the May issue of the journal Blood.

The gene that gives rise to HBZ is unusual because it lies on the wrong side of the virus’s DNA molecule. Such genes are known as antisense genes, and they have been observed in only a few retroviruses, including HIV.

A DNA molecule is somewhat like a railroad track that is twisted into a double helix. The two rails correspond to the complementary strands of the DNA backbone, while the ties correspond to the chemical base pairs that hold the two strands together and encode genetic information.

Normally, that genetic information is encoded only along one DNA 'rail,' or strand. That strand is called the sense strand. The opposite strand is the antisense sense strand, and it generally carries no genetic information.

But HTLV-1 is a rare exception. Of its eight genes, (some of which have information for more than one protein), seven lie along the sense strand. The eighth, which encodes the HBZ gene, is on the antisense strand (where it lies across from portions of three genes on the sense strand).

'Encoding a gene on the antisense strand is one more way for a small, compact virus to pack more genetic information or genes into a very small space, and it is why viruses like HTLV and HIV are called complex retrovi ruses,' says principal investigator Patrick L. Green, professor of veterinary biosciences and of molecular virology, immunology and medical genetics, and a Comprehensive Cancer Center researcher.

'Our study is the first to show that this novel protein is important for survival of the virus, which suggests that a drug that targets it might disrupt viral replication and provide a new therapy for infected people.'

Some 15 to 25 million people are infected with HTLV-1 worldwide, and 1 to 4 percent of them will eventually develop adult T-cell leukemia or lymphoma, a cancer that responds poorly to treatment and that can cause death within six months. In others, it causes a crippling and painful autoimmune-like disorder, tropical spastic paraparesis.

For this study, Green and his collaborators first looked at how loss of the HBZ protein affected the virus’s ability to infect and survive in its normal host immune cell, human T lymphocytes, or T cells, growing in culture.

They found little difference between the HBZ mutant HTLV and the normal virus. Both infected the cells and immortalized them equally well.

(Normally, T cells in culture die within a week or two. When the same cells are infected with HTLV-1, however, the virus causes changes that extend their life span indefinitely.)

Next, the scientists tested the ability of the mutant virus to infect and persist in a rabbit model, one of the few animals that duplicates human HTLV-1 infection. Those results indicated that the HBZ protein was required for prolonged infection in the body.

After eight weeks, rabbits that were infected with virus that lacked HBZ had one to 10 copies of the virus per 1,000 lymphocytes, whereas rabbits infected with normal virus had 50 to 100 HTLV-1 copies per 1,000 lymphocytes.

The virus may not survive well without HBZ because the immune system readily destroys cells infected by these viruses , Green says.

'We believe that HBZ acts as a brake on viral replication,' he says. 'Without HBZ, the virus replicates too fast, producing its proteins so quickly that the immune system readily detects infected cells and eliminates them.'

Green and his colleagues are now testing that hypothesis.

(Source: Eurekalert)
'"/>




Related medicine news :

1. Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified
2. Virus Level could Predict Cervical Cancer Risk
3. Ebola Virus - Outbreak Claims More Lives In Uganda.
4. Experimental treatment for Ebola Virus Shows promising results in mice
5. Virus Combats Brain Tumour
6. Virus killer
7. Pain Killers Keep the Virus Away
8. Measles Suppresses AIDS Virus
9. Virus connection to cervical injury
10. Virus Helps Remove Brain Cancer
11. Origin Of SARS Virus Discovered
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, ... (SCM) and spend management, today announced that Keppel Corporation has selected Apptricity Travel ... tracking. , “We are excited to announce the partnership between Keppel and ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & Morton celebrated the ... on Feb. 21. , The celebration began with a ribbon cutting event at ... construction team and tribal leadership. , Choctaw Nation Durant Regional Medical Clinic ...
(Date:2/21/2017)... ... 2017 , ... Doctors on Liens has announced the addition of Mendonca ... to its growing network of doctors in Central and Northern California. Dr. Mendonca specializes ... as whiplash, back pain, neck pain, hip and knee pain, and headaches. Specializing ...
(Date:2/21/2017)... ... ... Ray Insurance Agencies, a Dallas area firm providing asset protection services and ... six month charity event aimed at raising local support and donations that will be ... deadliest diseases in America; more than 7.5 million people die from cancer related disorders ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the further expansion of its eHealth App xChange™, providing clinical researchers more ... Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical trials ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... BEACH, Va. , Feb. 21, 2017  Global ... now covers Dermacell ® for breast ... foot ulcers. Dermacell is an advanced acellular dermal matrix ... Technologies, Inc. (NASDAQ: NVDQ ) ... the four major commercial health-care payers to review the ...
(Date:2/21/2017)... 2017   BeyondSpring Pharmaceuticals , a clinical ... innovative immuno-oncology cancer therapies, today announced that the ... Phase 2 trial of BeyondSpring,s innovative lead asset, ... cell lung cancer (NSCLC) with Docetaxel has been ... Clinical Immuno-Oncology Symposium in Orlando, Fla. ...
(Date:2/21/2017)... , Feb. 21, 2017 EMS Find, ... and web based platforms with focus on e-commerce, ... the signing of a worldwide, on-revocable and renewable ... full-service medical transportation company serving healthcare organizations and ... . EpicMD,s platform eliminates the ...
Breaking Medicine Technology: